REBECCA RICHARD: Open Payments
NPI 1881842649 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,444 in 65 payments from 15 companies in 2025. Trend: 2023 $818 · 2024 $567 · 2025 $1,444
Food & beverage: $1,444
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 19 | $497 |
| AstraZeneca Pharmaceuticals LP | 12 | $272 |
| GlaxoSmithKline, LLC. | 12 | $230 |
| Viatris Specialty LLC | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 4 | $88 |
| Grifols USA, LLC | 2 | $40 |
| Insmed, Inc. | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Amgen Inc. | 2 | $36 |
| Merck Sharp & Dohme LLC | 1 | $28 |
Products named: DUPIXENT, FASENRA, NUCALA, YUPELRI, TRELEGY ELLIPTA, TEZSPIRE, Prolastin-C Liquid, Arikayce.
Industry payments across LA — which companies pay providers there.
